Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric ...

Cancers that were once considered incurable now have new treatment options. Among these innovations are CAR-T (chimeric ...

Robert Holt is in the Basic and Translational Research Department, BC Cancer Research Institute, Vancouver V5Z1L3, Canada, in the Department of Medical Genetics, University of British Columbia, ...

A new technique may reprogram immune cells inside the body, offering faster, simpler, and more accessible cancer treatment.

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.

Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...

Chronic illnesses such as cancer and autoimmune disorders significantly strain both patients and healthcare systems. Traditional long-term drug therapies, which often have non-specific effects, can ...

Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers like leukemia and ...

Signaling is fundamental to how cells sense and respond to their environment—but in immune cells, those signals must be ...